title: Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.
abstract: OBJECTIVE
  To compare the virologic activity of continued lamivudine (3TC) versus a switch to delavirdine (DLV) when initiating protease inhibitor therapy in nucleoside-experienced patients.
  
  
  METHODS
  Randomized, open-label, multi-center study.
  
  
  METHODS
  Adult AIDS clinical trials units.
  
  
  METHODS
  Protease and non-nucleoside reverse transcriptase inhibitor-naive patients who had received 3TC plus zidovudine (ZDV), stavudine (d4T), or didanosine (ddl) for at least 24 weeks.
  
  
  METHODS
  Patients with plasma HIV-1 RNA levels > 500 copies/ml who previously received d4T + 3TC or ddI + 3TC were randomized to ZDV + 3TC + indinavir (IDV) or ZDV + DLV + IDV.
  
  
  METHODS
  Primary endpoints were the proportion of patients with plasma HIV-1 RNA levels < or = 200 copies/ml at 24 weeks, and occurrence of serious adverse events. The proportion of patients with plasma HIV-1 RNA levels < or = 200 copies/ml at week 48 was a secondary endpoint.
  
  
  RESULTS
  At week 24, 58% of subjects in the ZDV + 3TC + IDV arm and 73% in the ZDV + DLV + IDV arm had plasma HIV-1 RNA levels < or = 200 copies/ml (P = 0.29). At week 48, plasma HIV-1 RNA levels were < or = 200 copies/ml in 48% and 83%, respectively (P = 0.007). Rash and hyperbilirubinemia occurred more frequently in the DLV arm than in the 3TC arm. Steady-state plasma IDV levels were higher among patients in the DLV arm as compared with the 3TC arm.
  
  
  CONCLUSIONS
  Substituting DLV for 3TC when adding IDV improved virologic outcome in nucleoside-experienced patients. This result might be explained, in part, by the positive effect of DLV on IDV pharmacokinetics.
authors.affiliation: Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver 80262, USA.
authors.forename: D R
authors.initials: DR
authors.lastname: Kuritzkes
authors.forename: R L
authors.initials: RL
authors.lastname: Bassett
authors.forename: V A
authors.initials: VA
authors.lastname: Johnson
authors.forename: I C
authors.initials: IC
authors.lastname: Marschner
authors.forename: J J
authors.initials: JJ
authors.lastname: Eron
authors.forename: J P
authors.initials: JP
authors.lastname: Sommadossi
authors.forename: E P
authors.initials: EP
authors.lastname: Acosta
authors.forename: R L
authors.initials: RL
authors.lastname: Murphy
authors.forename: K
authors.initials: K
authors.lastname: Fife
authors.forename: K
authors.initials: K
authors.lastname: Wood
authors.forename: D
authors.initials: D
authors.lastname: Bell
authors.forename: A
authors.initials: A
authors.lastname: Martinez
authors.forename: C B
authors.initials: CB
authors.lastname: Pettinelli
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D020008:Delavirdine / Q000627:therapeutic use*; D005260:Female; D017320:HIV Protease Inhibitors / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D019469:Indinavir / Q000097:blood / Q000627:therapeutic use*; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D018119:Stavudine / Q000627:therapeutic use*; D013997:Time Factors; D019562:Viral Load; D015215:Zidovudine / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D019469:Indinavir; D018119:Stavudine; D020008:Delavirdine